expect result
set report open next week tuesday
februari follow lower revenu expect cvg busi
disclos morgan healthcar confer januari
expect fairli unev quarter financi perspect see limit
downsid street top- bottom-lin expect head
think updat street ep estim exclud
outlier rang appropri factor cvg tax fx
headwind result see upsid vs downsid risk next week
print particularli current depress valuat ep
ev/ebitda vs peer quarter line
street report revenu vs vs
organ growth ep vs turn guidanc expect
manag formal lower organ sale guidanc line
cfo commentari morgan healthcar confer reiter
cash ep outlook
model sale report organ vs
street fx headwind assumpt
street jpme sale vs street howev
model lower contribut acquisit vs street
drive organ growth bar consensu vs
segment street cvg entir
 hf street rtg
expect intelli continu drive share gain pain therapi
vs street touch diabet street
mitg call expect signific focu impact
fx tax compani bottom line updat
headwind dcb lvad call healthcar confer
tick overal cvg growth discuss robust
pipelin import upcom dataset hr europcr
cardiac vascular group cvg forecast organ
growth due street model recogn
commentari morgan healthcar confer note cvg
area widespread street estim due model bake
compani commentari growth expect organ rang
vs
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
drive lower cvg expect share loss expect
lvad abbott heartmat destin therapi dt approv octob
guidelin chang around heart transplant priorit meta-
analysi publish jaha decemb highlight potenti danger
paclitaxel-co devic dcb dess view overst base
data present linc comparison
larg dcb competitor said volum slow decemb follow meta-
analysi rebound follow januari dear doctor letter sub-
segment project heart failur hf sale
aortic peripher vascular apv sale coronari
structur heart csh sale
restor therapi group rtg model organ growth
street specif estim spine revenu
brain therapi sale pain therapi sale
specialti therapi sale line focus
anticip beat pain therapi expect put anoth strong
quarter compani intelli product continu gain share
conserv model world-wide growth vs
us growth vs
diabet model organ growth street
well commun compani diabet growth set
step significantli organ rate saw due
compani comp get difficult sequenti
organ growth organ growth furthermor last
four quarter outsiz growth divis benefit bolu
announc exit insulin pump market signific backlog
patient wait onboard follow compani initi suppli
constraint earli roll-out period still expect diabet divis
accret overal growth go forward model high-single-
low-double-digit growth segment pipelin
medtron second gener hybrid closed-loop pump meal-tim correct
bolus expect hear ada june
commerci launch
minim invas therapi group mitg model organ
growth sale ahead street forecast
sale surgic innov
remain patient monitor recoveri busi look updat
compani progress surgic robot front expect manag
reiter expect launch late big question call
system compar js acquir auri see
yesterday note confid manag timelin
 closer commerci higher credibl asset well
look manag respons impact posit
 estim lower gross margin off-set lower
oper spend assumpt drive in-lin oper margin forecast
gross margin street off-set lower
oper spend assumpt sg
oper line model expens vs street
non-oper incom street interest expens
street in-lin tax rate drive bottom line one cent
lower consensu vs
expect manag reiter organ sale guidanc
midpoint rang rais organ growth expect
higher end rang call grow
organ cfo parkhil suggest investor shift
expect closer middl rang morgan healthcar
confer base lower outlook cvg growth bottom line
expect ep guidanc maintain expect
earli commentari ep progress greater focu one
quarter left year end compani provid updat outlook
fx impact see top bottom line well tax outlook
settl regul establish late model project
headwind sale acquisit benefit result
organ top-lin growth year tax model
step project point tax worth
ep
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat-and-rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least line end market growth plu see
number underappreci data present transform new product
launch appear fulli appreci street conserv
leav potenti catalyst see come upsid vs forecast
manag set appropri conserv bar long-rang top-lin
earn progress june analyst day see meaning upsid
street estim year ahead potenti multipl expans
dec price target share base peer
price-to-earnings multipl appli calendar ep estim
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
